Report Shows Record Number of Cancer Drugs in Development

Publication
Article
OncologyONCOLOGY Vol 23 No 4
Volume 23
Issue 4

Responding to President Obama’s call for “a cure for cancer in our time,” the Pharmaceutical Research and Manufacturers of America recently delivered a new report on drugs in the research pipeline for cancer.

Responding to President Obama's call for "a cure for cancer in our time," the Pharmaceutical Research and Manufacturers of America recently delivered a new report on drugs in the research pipeline for cancer. The report shows that America's pharmaceutical research and biotechnology companies are testing a record 861 new cancer medicines and vaccines. The drugs listed in the report are being tested in human clinical trials or are awaiting approval by the US Food and Drug Administration.

Articles in this issue
Despite Past Disappointments the Future of Melanoma Therapy Appears Bright
Everolimus Approved for Advanced Kidney Cancer
Report Shows Record Number of Cancer Drugs in Development
Sunitinib Study in Pancreatic Cancer Stopped Early After Significant Benefit Seen
Black Cohosh (Cimicifuga racemosa)
Black Cohosh (Cimicifuga racemosa)
Clinical Trials and Radiation Oncology Technologies
Evaluating Advanced Technologies in Radiation Oncology: When and How Should Randomized Trials Be Done?
Current Status and Future Potential of Advanced Technologies in Radiation OncologyPart 2. State of the Science by Anatomic Site
Health Literacy: Improving Patient Understanding
Health Literacy, Communication, and Treatment Decision-Making in Older Cancer Patients
The Role of Adjuvant Radiation in Endometrial Cancer
The Role of Adjuvant Radiation in Endometrial Cancer
Resolving the Confusion Surrounding Adjuvant Radiation in Endometrial Cancer
Studies of Adjuvant Treatment for Endometrial Cancer
Landmark Study Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer
Maintenance Rituximab Useful in Advanced Indolent Lymphoma
Recent Videos
Related Content
42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
May 29th 2025
Article
Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD
May 27th 2025
Article
Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.

48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

Anushree Iyengar;Sandhya Mehta;Hannah Barman;Nivedita Rangarajan;Sue-Ann Woo;Simone T. Sredni;Rosemarie Di Donato;Safak Simsek;Erinn P. Downs;Aziza Nassar;Darren M. Wilson;Katherine Krieser;Elise Bieri Patzke;Natalie Kyek;Jason Hipp;Tyler Wagner, PhD
May 25th 2025
Article
49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

Katheryn Moreira;Kathryn Hudson;Wambui Gathirua-Mwangi;Zhanglin Lin Cui;Madeline Richey;Brenda Grimes;Jingru Wang;Astra Liepa;Erich Brechtelsbauer;Raisa Volodarsky;Hatem Soliman, MD
May 24th 2025
Article